Clinical Trial Results: Pilot Study of an NTproBNP Guided Strategy of Cardioprotection [Phase 1, Phase 2]

View source ↗

Summary

Pilot study results explore an NTproBNP-guided strategy to cardioprotection during chemotherapy in patients with cardiotoxicity risks.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cardiomyopathies
• Cardiotoxicity
• Heart Failure
• Lymphoma
• Toxicity Due to Chemotherapy

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Cardiotoxicity, Toxicity Due to Chemotherapy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-06-15